Publicaciones en colaboración con investigadoras/es de Hospital Sierrallana (98)

2024

  1. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients

    Seminars in Arthritis and Rheumatism, Vol. 55

  3. Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients

    Clinical and Experimental Rheumatology

  4. Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 8, pp. 1839-1851

2021

  1. Amyotrophic lateral sclerosis (ALS), cancer, autoimmunity and metabolic disorders: An unsolved tantalizing challenge

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1269-1278

  2. Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

  3. Clinical and preclinical evidence of somatosensory involvement in amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1257-1268

  4. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  5. European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain

    Antibiotics, Vol. 10, Núm. 1, pp. 1-15

  6. Timing and characteristics of venous thromboembolism after noncancer surgery

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 9, Núm. 4, pp. 859-867.e2

  7. Treatment with tofacitinib in refractory psoriatic arthritis: A national multicenter study of the first 87 patients in clinical practice

    Journal of Rheumatology, Vol. 48, Núm. 10, pp. 1552-1558

2020

  1. A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis

    Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 21, Núm. 3-4, pp. 252-262

  2. ALS-derived fibroblasts exhibit reduced proliferation rate, cytoplasmic TDP-43 aggregation and a higher susceptibility to DNA damage

    Journal of Neurology, Vol. 267, Núm. 5, pp. 1291-1299

  3. Anti-il-6 receptor tocilizumab in refractory graves’ orbitopathy: National multicenter observational study of 48 patients

    Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-15

  4. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

    Lupus, Vol. 29, Núm. 12, pp. 1556-1565

  5. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 89-98

  6. Dermic-derived fibroblasts for the study of amyotrophic lateral sclerosis

    Neural Regeneration Research, Vol. 15, Núm. 11, pp. 2043-2044